Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis.

ERJ Open Res · 2026 · PMC12969660 · PMID 41809856

Europe PMC DOI

hedged sentences

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significancep=0.13not close (p > 0.1)

A trend towards reduction of blood IL-13 + ILC2s was observed in patients receiving benralizumab; although this difference did not reach statistical significance (baseline 179 (0–288), post-treatment 0 (0–0) cells per mL; p=0.13).

also in 111,027 other papers

a decreasing trendno p-value reported

Sputum eosinophils showed a decreasing trend in both treatment groups, although this was not statistically significant (p>0.05) ( figure 1a ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.